N-Myc Proto-Oncogene Protein
"N-Myc Proto-Oncogene Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A basic helix-loop-helix leucine zipper (bHLHZ) transcription factor and proto-oncogene protein that functions in cell growth and proliferation. In mammals, it is highly expressed in the brain during embryogenesis and is essential for brain development; it is not expressed in adult tissues. Amplification or overexpression of N-Myc occurs in at least 20% of tumors and is associated with a poor prognosis in cases of NEUROBLASTOMA; ALVEOLAR RHABDOMYOSARCOMA; SMALL CELL LUNG CARCINOMA; and neuroendocrine prostate cancer.
Descriptor ID |
D000071447
|
MeSH Number(s) |
D12.776.260.103.500.625 D12.776.260.108.092.625 D12.776.624.664.700.158 D12.776.930.125.500.563 D12.776.930.127.092.625
|
Concept/Terms |
N-Myc Proto-Oncogene Protein- N-Myc Proto-Oncogene Protein
- N Myc Proto Oncogene Protein
- Proto-Oncogene Protein, N-Myc
- BHLHE37 Protein
- NMYC Protein
- Class E Basic Helix-Loop-Helix Protein 37
- Class E Basic Helix Loop Helix Protein 37
- N-Myc Protein
- N Myc Protein
- MYCN Protein
|
Below are MeSH descriptors whose meaning is more general than "N-Myc Proto-Oncogene Protein".
Below are MeSH descriptors whose meaning is more specific than "N-Myc Proto-Oncogene Protein".
This graph shows the total number of publications written about "N-Myc Proto-Oncogene Protein" by people in this website by year, and whether "N-Myc Proto-Oncogene Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2009 | 0 | 3 | 3 |
2011 | 0 | 2 | 2 |
2012 | 0 | 3 | 3 |
2013 | 0 | 2 | 2 |
2014 | 0 | 1 | 1 |
2015 | 0 | 2 | 2 |
2017 | 2 | 1 | 3 |
2018 | 1 | 0 | 1 |
2019 | 0 | 1 | 1 |
2020 | 2 | 0 | 2 |
2021 | 3 | 0 | 3 |
2022 | 0 | 1 | 1 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "N-Myc Proto-Oncogene Protein" by people in Profiles.
-
The DNA methylome of pediatric brain tumors appears shaped by structural variation and predicts survival. Nat Commun. 2024 Aug 08; 15(1):6775.
-
The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN-amplified neuroblastoma. Sci Adv. 2024 May 31; 10(22):eadm9449.
-
Ferroptosis vulnerability in MYCN-driven neuroblastomas. Clin Transl Med. 2022 08; 12(8):e963.
-
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma. Nat Commun. 2022 06 28; 13(1):3728.
-
Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study. Cell Rep Med. 2022 06 21; 3(6):100644.
-
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 08 01; 45(8):1075-1081.
-
Restoration of the molecular clock is tumor suppressive in neuroblastoma. Nat Commun. 2021 06 28; 12(1):4006.
-
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia. 2021 06; 23(6):624-633.
-
Association of heterogeneous MYCN amplification with clinical features, biological characteristics?and outcomes in neuroblastoma: A report from the Children's Oncology Group. Eur J Cancer. 2020 07; 133:112-119.
-
Optimization of percutaneous biopsy for diagnosis and pretreatment risk assessment of neuroblastoma. Pediatr Blood Cancer. 2020 05; 67(5):e28153.